Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
22 papers
Research shows several different ways can help with sadness or low mood. Right now, the strongest clinical evidence for a fast-acting drug comes from ketamine and its approved form esketamine. At the same time, a wave of studies on classic psychedelics (psilocybin, LSD, DMT) and entactogens (MDMA) looks promising, especially when the drug is given together with careful psychological support. However, most psychedelic studies are still small or early-stage. They often rely on the setting, preparation, and therapy as part of the treatment, so researchers say we need larger, controlled trials and more long-term safety data. Also, non-drug options like brain stimulation and standard psychotherapies remain important parts of treatment plans and have mixed but useful evidence.
This meta-analysis combined 241 effect sizes from 114 studies to test how six habitual emotion-regulation strategies relate to symptoms of anxiety, depression, eating disorders, and substance-related problems. Rumination showed the strongest (large) link with symptoms. Avoidance, problem solving, and suppression showed medium-to-large links, while reappraisal and acceptance showed smaller (small-to-medium)…
The authors reviewed psychedelic-assisted psychotherapy studies published from 1993 to 2017 to see how many people of color took part. They found 18 studies with about 280 people. About 82% of participants were non-Hispanic White, while only small percentages were African American, Latino, Asian, indigenous, or mixed race. Because so…
Researchers reviewed many outcome studies and meta-analyses of psychodynamic therapy, which is a type of talking therapy that explores feelings, relationships, and past experiences. They found that psychodynamic therapy often works better than doing nothing (for example being on a waitlist, getting only usual care, or a placebo) for depression,…
This review looked at many studies about classic psychedelics (like psilocybin and LSD), MDMA, ketamine, and plant medicines (like ayahuasca). The authors explain how these drugs can change the brain’s wiring, calm inflammatory processes, and shift key brain chemicals. Those actions may help explain why small clinical trials and animal…
This paper reviews the recent comeback of psychedelic research and points out that much of that work borrows from indigenous healing traditions. The authors say Indigenous people, ethnic and racial minorities, women, and other marginalized groups are often left out of research and the mainstream story about psychedelic medicine. The…
Researchers collected and read 15 studies where patients described their own experiences with psychedelic treatments for mental disorders. These studies looked at about 180 patient accounts across different drugs and different illnesses. Even though the drugs and treatment settings were very different, many patients described similar helpful processes, such as…
Researchers around the world have started clinical studies again to see if psychedelic drugs can help treat serious mental health problems. This work picks up after research that stopped around the 1950s. Scientists are running controlled studies to test whether these substances can safely reduce problems like depression, anxiety, addiction…
This paper reviews clinical and lab studies about psychedelic therapy, which means using a psychedelic drug together with psychological support. The authors say this approach looks promising for several different mental health problems that share rigid or harmful patterns of feeling, thinking, or acting — especially major depression, depression that…
This paper is a review of research about psychedelic drugs and whether they could help with mood and anxiety problems. It explains that these drugs were used for thousands of years in some cultures, then were banned in the 1960s which slowed scientific study. The authors describe a new wave…
This article is a broad review of the new psychedelic industry. The authors look at how psychedelic drugs and clinics moved from decades-old research into a fast-growing business with hundreds of companies and big investment. They describe what companies are trying to sell, point out major scientific, legal, and ethical…
This review looks at recent research where drugs like MDMA and psilocybin are given inside carefully run therapy programs. People get hours of preparation, one or more drug sessions, and several follow-up therapy sessions to help make sense of the experience. Trials so far show big improvements for some people…
This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…
